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Thus anakinra therapy is warranted in patients with inﬂamma-
tory disorders associated with mutation in CIAS1, but physi-
cians must be aware of the increased risk of infection associated
with this drug.
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[18F]FDG-PET of giant-cell aortitis
SIR, A 74-yr-old woman was admitted to hospital with a 6-month
history of weakness, decreasing appetite, vomiting, abdominal pain
and weight loss of 14 kg. Laboratory studies showed that the white
FIG. 1. FDG-PET of a giant cell arteritis patient, which clearly demonstrates pathologically elevated glucose uptake within the vessel
wall of the whole aorta (arrow).
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cell count was 12 100/mm3, the haemoglobin concentration
was 9.4 g/dl, the haematocrit was 29.1%, the platelet count was
494 000/mm3and theC-reactive proteinwas 141mg/l.Gastroscopy,
colonoscopy and CT scanning showed no abnormalities.
For further evaluation, the patient was admitted for [18F]FDG-
PET, which clearly demonstrated pathologically elevated glucose
uptake within the vessel wall of the whole aorta (Fig. 1A, arrow)
and its main thoracic and abdominal branches. The diagnosis of
large-vessel vasculitis was subsequently conﬁrmed by the ﬁnding
of giant cell inﬁltration (Fig. 1B, arrow) with thickening of
all temporal artery layers and consecutive stenosis of the lumen.
The patient was treated with prednisone and recovery was
unremarkable.
Due to its high sensitivity, especially in the state of
active inﬂammation [1], [18F]FDG-PET might become a
valuable diagnostic tool in the management of large-vessel
inﬂammation.
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Congenital heart block associated with a maternal
anti-HsEg5-like autoantibody
SIR, Congenital heart block (CHB) is a rare (1:20 000) disease,
and in 70% of cases there are no coexisting cardiac malforma-
tions [1]. In this subsect, up to 90% [2, 3] are associated with, if
not directly caused by, maternal autoantibodies (Abs) against
SSA/SSB (cardiac manifestation of neonatal lupus erythematosus),
independently of whether maternal SLE or SS is manifested. Via
active placental transfer (increasing after 16 weeks’ gestation), IgG
antibodies (Abs) gain access to the fetal heart during a vulnerable
phase (from week 16 until shortly after birth), when the main
cardiac development is complete and physiological apoptotic
FIG. 1. Continued. Histological conﬁrmation of giant cell arteritis, by ﬁnding of giant cell inﬁltration (arrow) with thickening of all
temporal artery layers and consecutive stenosis of the lumen.
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